Cointime

G1 Therapeutics

company

About

G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.

  • 101 - 250

Highlights

Total Funding Amount
$100M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$100M
Industries
Biotechnology,Developer Platform,Medical,Therapeutics
Founded date
Jan 1, 2008
Number Of Employee
101 - 250
Operating Status
Active

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$100M
G1 Therapeutics has raised a total of $100M in funding over 2 rounds. Their latest funding was raised on Jun 1, 2020 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 1, 2020 Post-IPO Debt $100M 1 Hercules Capital — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
G1 Therapeutics is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
Cointime
เนื้อหา
บริษัท